Loading company
RenovoRx, Inc.
RNXT · Nasdaq · ·
$1.57+1.0%Sep 29 close
- 1M
- -6.3%
- 6M
- +46.3%
- 1Y
- +23.2%
- 5Y
- -77.7%
RNXT · Nasdaq · ·
$1.57+1.0%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $909K | $422K | +115.40% |
| Profit | -$2.9M | -$2.9M | -0.55% |
| Profit per share | -$0.06 | -$0.08 | +25.00% |
| Free Cash Flow | -$2.9M | -$2.3M | -27.63% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
RenovoRx, Inc. has no earnings call transcript available.
“We made important strides in the first quarter of 2026 with strong commercial adoption of the TAMP platform enabled by RenovoCath, resulting in record quarterly revenue exceeding 50% of the revenue we generated in all of 2025,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from RenovoRx, Inc.’s Item 2.02 8-K filed May 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.